Explore
Trendline
Pfizer Secures Exclusive Rights to Starna Therapeutics' In Vivo CAR-T Programs for Autoimmune Diseases
Pfizer Secures Exclusive Rights to Starna Therapeutics' In Vivo CAR-T Programs for Autoimmune Diseases
Read More
Trendline
Pfizer Secures Exclusive Licensing Deal with Starna Therapeutics for Autoimmune Disease RNA Medicines
Pfizer Secures Exclusive Licensing Deal with Starna Therapeutics for Autoimmune Disease RNA Medicines
Read More
Trendline
Novartis CEO Warns US Biotech Investment Curbs in China Could Impede Drug Development
Novartis CEO Warns US Biotech Investment Curbs in China Could Impede Drug Development
Read More
Trendline
Sanofi Explores Potential $43 Billion Acquisition of Insmed Amidst Dupixent Patent Concerns
Sanofi Explores Potential $43 Billion Acquisition of Insmed Amidst Dupixent Patent Concerns
Read More
Trendline
Eli Lilly CEO David Ricks Pursues Strategic Acquisitions to Diversify Growth Beyond Weight-Loss Drugs
Eli Lilly CEO David Ricks Pursues Strategic Acquisitions to Diversify Growth Beyond Weight-Loss Drugs
Read More
Trendline
Sanofi Considers Acquisition of U.S. Drugmaker Insmed Inc. to Address Patent Cliff
Sanofi Considers Acquisition of U.S. Drugmaker Insmed Inc. to Address Patent Cliff
Read More
Trendline
Eli Lilly and Pfizer Compete for Pharmaceutical Market Dominance Amidst Shifting Growth Strategies
Eli Lilly and Pfizer Compete for Pharmaceutical Market Dominance Amidst Shifting Growth Strategies
Read More
Trendline
Sanofi Reportedly Explores Acquisition of Insmed Amidst Post-Dupixent Strategy
Sanofi Reportedly Explores Acquisition of Insmed Amidst Post-Dupixent Strategy
Read More
Trendline
Jack Ma Increases Alibaba Stake Amid AI Expansion and Public Re-emergence
Jack Ma Increases Alibaba Stake Amid AI Expansion and Public Re-emergence
Read More
Trendline
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Read More
Trendline
Insilico Medicine Advances AI-Driven Drug Discovery in China's Pharmaceutical Sector
Insilico Medicine Advances AI-Driven Drug Discovery in China's Pharmaceutical Sector
Read More
Trendline
Johnson Johnson Acquires U.S. Biotech Firm Ollin Biosciences for Up to $3.325 Billion
Johnson Johnson Acquires U.S. Biotech Firm Ollin Biosciences for Up to $3.325 Billion
Read More